Vani Lakshminarayanan - Search Results

Year	Number of Results
2011	1
2012	1
2014	1
2015	1
2016	2
2017	1
2018	1
2021	1
2024	0

1

Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Supekar NT, Lakshminarayanan V, Capicciotti CJ, Sirohiwal A, Madsen CS, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ. Supekar NT, et al. Among authors: lakshminarayanan v. Chembiochem. 2018 Jan 18;19(2):121-125. doi: 10.1002/cbic.201700424. Epub 2017 Nov 30. Chembiochem. 2018. PMID: 29120508 Free PMC article.

2

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.

Sweet K, Song Q, Loza MJ, McInnes IB, Ma K, Leander K, Lakshminarayanan V, Franks C, Cooper P, Siebert S. Sweet K, et al. Among authors: lakshminarayanan v. RMD Open. 2021 May;7(2):e001679. doi: 10.1136/rmdopen-2021-001679. RMD Open. 2021. PMID: 34011674 Free PMC article. Clinical Trial.

3

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.

Pathangey LB, Lakshminarayanan V, Suman VJ, Pockaj BA, Mukherjee P, Gendler SJ. Pathangey LB, et al. Among authors: lakshminarayanan v. Biomolecules. 2016 Jun 29;6(3):31. doi: 10.3390/biom6030031. Biomolecules. 2016. PMID: 27367740 Free PMC article.

4

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

Lakshminarayanan V, Supekar NT, Wei J, McCurry DB, Dueck AC, Kosiorek HE, Trivedi PP, Bradley JM, Madsen CS, Pathangey LB, Hoelzinger DB, Wolfert MA, Boons GJ, Cohen PA, Gendler SJ. Lakshminarayanan V, et al. PLoS One. 2016 Jan 20;11(1):e0145920. doi: 10.1371/journal.pone.0145920. eCollection 2016. PLoS One. 2016. PMID: 26788922 Free PMC article.

5

Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.

Abdel-Aal AB, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ. Abdel-Aal AB, et al. Among authors: lakshminarayanan v. Chembiochem. 2014 Jul 7;15(10):1508-13. doi: 10.1002/cbic.201402077. Epub 2014 May 30. Chembiochem. 2014. PMID: 24890740 Free PMC article.

6

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.

Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ. Thompson P, et al. Among authors: lakshminarayanan v. Chem Commun (Camb). 2015 Jun 25;51(50):10214-7. doi: 10.1039/c5cc02199e. Epub 2015 May 29. Chem Commun (Camb). 2015. PMID: 26022217 Free PMC article.

7

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Lakshminarayanan V, et al. Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):261-6. doi: 10.1073/pnas.1115166109. Epub 2011 Dec 14. Proc Natl Acad Sci U S A. 2012. PMID: 22171012 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year